NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free ALLR Stock Alerts $0.50 -0.05 (-9.07%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.48▼$0.5350-Day Range$0.50▼$5.3052-Week Range$0.48▼$269.80Volume2.30 million shsAverage Volume4.01 million shsMarket Capitalization$1.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Allarity Therapeutics alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Allarity Therapeutics Stock (NASDAQ:ALLR)Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More ALLR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLR Stock News HeadlinesMay 20, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementMay 15, 2024 | investorplace.comALLR Stock Earnings: Allarity Therapeutics Reported Results for Q1 2024May 14, 2024 | globenewswire.comAllarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesMay 7, 2024 | globenewswire.comAllarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockMay 6, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 6, 2024 | finance.yahoo.comAllarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 6, 2024 | globenewswire.comAllarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 2, 2024 | msn.comWhy Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?May 2, 2024 | benzinga.comNasdaq Jumps Over 100 Points; Kellanova Posts Upbeat ResultsMay 2, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 39% Today?May 2, 2024 | finance.yahoo.comAllarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerMay 2, 2024 | globenewswire.comAllarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerApril 29, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 29, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 17, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)April 17, 2024 | finance.yahoo.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 17, 2024 | globenewswire.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 12, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 41% Today?April 4, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitApril 4, 2024 | msn.comAllarity Therapeutics to implement 1-for-20 reverse stock splitApril 4, 2024 | globenewswire.comAllarity Therapeutics Announces 1-for-20 Reverse Stock SplitMarch 27, 2024 | globenewswire.comAllarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerMarch 25, 2024 | globenewswire.comAllarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)March 8, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateMarch 8, 2024 | benzinga.comAllarity Therapeutics: Q4 Earnings InsightsSee More Headlines Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/09/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,900,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-96.94% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.62) per share Price / Book-0.03Miscellaneous Outstanding Shares2,390,000Free Float2,384,000Market Cap$1.20 million OptionableNot Optionable Beta0.41 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Thomas H. Jensen (Age 46)Founder, CEO, Senior VP of Investor Relations & Director Ms. Joan Y. Brown (Age 70)Chief Financial Officer Comp: $180kMr. Peter Buhl Jensen Adj Professor (Age 69)M.D., M.D., Ph.D., Ph.D., Co-Founder Comp: $546.08kDr. Steen Meier Knudsen Ph.D. (Age 63)Founder & Chief Scientific Officer Comp: $185.11kKey CompetitorsLixte BiotechnologyNASDAQ:LIXTHoth TherapeuticsNASDAQ:HOTHProtagenic TherapeuticsNASDAQ:PTIXClever LeavesNASDAQ:CLVRSynaptogenixNASDAQ:SNPXView All Competitors ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed in 2024? Allarity Therapeutics' stock was trading at $11.0220 on January 1st, 2024. Since then, ALLR stock has decreased by 95.5% and is now trading at $0.5010. View the best growth stocks for 2024 here. Are investors shorting Allarity Therapeutics? Allarity Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 468,800 shares, an increase of 111.9% from the April 30th total of 221,200 shares. Based on an average daily trading volume, of 3,540,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.0% of the shares of the stock are short sold. View Allarity Therapeutics' Short Interest. When is Allarity Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ALLR earnings forecast. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) issued its earnings results on Tuesday, May, 14th. The company reported ($22.14) EPS for the quarter. When did Allarity Therapeutics' stock split? Shares of Allarity Therapeutics reverse split before market open on Tuesday, April 9th 2024. The 1-20 reverse split was announced on Tuesday, April 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLR) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.